References of "PAQUOT, Nicolas"
     in
Bookmark and Share    
See detailAutoregulation of endogenous glucose production in man.
Tappy, L.; Tounian, P.; PAQUOT, Nicolas ULg

Poster (1996)

Detailed reference viewed: 4 (0 ULg)
See detailEffects of glucagon on fructose-induced alterations of glucose metabolism in man.
Paquot, Nicolas ULg; Schneiter, Ph; Jéquier, E. et al

in Reproduction Nutrition Development (1996), 36

Detailed reference viewed: 2 (0 ULg)
See detailContribution à l'étude de l'insulinorésistance chez l'homme.
PAQUOT, Nicolas ULg

Doctoral thesis (1996)

Detailed reference viewed: 3 (0 ULg)
See detailEffects of ingested fructose and infused glucagon on endogenous glucose production in obese NIDDM patients, obese non-diabetic subjects, and healthy subjects.
Paquot, Nicolas ULg; Schneiter, P.; Jequier, E. et al

in Diabetologia (1996), 39(5), 580-6

Increased endogenous glucose production (EGP) and gluconeogenesis contribute to the pathogenesis of hyperglycaemia in non-insulin-dependent diabetes mellitus (NIDDM). In healthy subjects, however, EGP ... [more ▼]

Increased endogenous glucose production (EGP) and gluconeogenesis contribute to the pathogenesis of hyperglycaemia in non-insulin-dependent diabetes mellitus (NIDDM). In healthy subjects, however, EGP remains constant during administration of gluconeogenic precursors. This study was performed in order to determine whether administration of fructose increases EGP in obese NIDDM patients and obese non-diabetic subjects. Eight young healthy lean subjects, eight middle-aged obese NIDDM patients and seven middle-aged obese non-diabetic subjects were studied during hourly ingestion of 13C fructose (0.3 g.kg fat free mass-1.h-1) for 3 h. Fructose failed to increase EGP (measured with 6,6 2H glucose) in NIDDM (17.7 +/- 1.9 mumol.kg fat free mass-1.min-1 basal vs 15.9 +/- 0.9 after fructose), in obese non-diabetic subjects (12.1 +/- 0.5 basal vs 13.1 +/- 0.5 after fructose) and in lean healthy subjects (13.3 +/- 0.5 basal vs 13.8 +/- 0.6 after fructose) although 13C glucose synthesis contributed 73.2% of EGP in lean subjects, 62.6% in obese non-diabetic subjects, and 52.8% in obese NIDDM patients. Since glucagon may play an important role in the development of hyperglycaemia in NIDDM, healthy subjects were also studied during 13C fructose ingestion + hyperglucagonaemia (232 +/- 9 ng/l) and during hyperglucagonaemia alone. EGP increased by 19.8% with ingestion of fructose + glucagon (p < 0.05) but remained unchanged during administration of fructose or glucagon alone. The plasma 13C glucose enrichment was identical after fructose ingestion both with and without glucagon, indicating that the contribution of fructose gluconeogenesis to the glucose 6-phosphate pool was identical in these two conditions. We concluded that during fructose administration: 1) gluconeogenesis is increased, but EGP remains constant in NIDDM, obese non-diabetic, and lean individuals; 2) in lean individuals, both an increased glucagonaemia and an enhanced supply of gluconeogenic precursors are required to increase EGP; this increase in EGP occurs without changes in the relative proportion of glucose 6-phosphate production from fructose and from other sources (i.e. glycogenolysis + gluconeogenesis from non-fructose precursors). [less ▲]

Detailed reference viewed: 15 (0 ULg)
See detailComment évaluer la sécrétion insulinique en pratique?
Scheen, A. J.; Paquot, Nicolas ULg; Letiexhe, M. R. et al

in Diabète & Métabolisme (1995), 21(6), 458-64

Detailed reference viewed: 7 (0 ULg)
See detailLe cas clinique du mois. Rémission spontanée prolongée d'un diabète de type 1 typique
Scheen, A. J.; Letiexhe, M. R.; Paquot, Nicolas ULg et al

in Revue Médicale de Liège (1995), 50(9), 363-4

Detailed reference viewed: 16 (0 ULg)
See detailLe cas clinique du mois. A propos d'un cas de sécrétion ectopique d'ACTH
Biessaux, Yves ULg; Paquot, Nicolas ULg; Scheen, A. J. et al

in Revue Médicale de Liège (1995), 50(2), 55-6

Detailed reference viewed: 18 (0 ULg)
See detailEffects of infused sodium lactate on glucose and energy metabolism in healthy humans.
Paquot, Nicolas ULg; Schneiter, P.; Cayeux, M. C. et al

in Diabètes & Métabolism (1995), 21(5), 345-52

To assess the effects of lactate on glucose metabolism, sodium lactate (20 mumol.kg-1.min-1) was infused into healthy subjects in basal conditions and during application of a hyperinsulinaemic (6 pmol.kg ... [more ▼]

To assess the effects of lactate on glucose metabolism, sodium lactate (20 mumol.kg-1.min-1) was infused into healthy subjects in basal conditions and during application of a hyperinsulinaemic (6 pmol.kg-1.min-1) euglycaemic clamp. Glucose rate of appearance (GRa) and disappearance (GRd) were measured from plasma dilution of infused U- 13C glucose, and glucose oxidation (G(ox)) from breath 13CO2 and plasma 13C glucose. In basal conditions, lactate infusion did not alter G(ox) (8.8 +/- 0.9 vs 9.2 +/- 1.1 mumol.kg-1.min-1), while GRa slightly decreased from 15.2 +/- 0.8 basal to 13.9 +/- 0.9 mumol.kg-1.min-1 after lactate (p < 0.05). During a hyperinsulinaemic clamp, hepatic glucose production was completely suppressed with or without lactate. Lactate decreased G(ox) from 17.1 +/- 0.4 to 13.4 +/- 1.2 mumol.kg-1.min-1 (p < 0.05), whereas GRd was unchanged (39.7 +/- 3.6 vs 45.6 +/- 2.6 mumol.kg-1.min-1. It is concluded that infusion of lactate in basal conditions does not increase GRa or interfere with peripheral glucose oxidation, and that during hyperinsulinaemia lactate decreases glucose oxidation but does not alter hepatic or peripheral insulin sensitivity. [less ▲]

Detailed reference viewed: 8 (2 ULg)
See detailAssessment of glucose metabolism in humans with the simultaneous use of indirect calorimetry and tracer techniques.
Tappy, L.; Paquot, Nicolas ULg; Tounian, P. et al

in Clinical Physiology (1995), 15(1), 1-12

Concomitant measurements of sytemic glucose delivery and carbohydrate oxidation are frequently performed in human investigations. Systemic glucose delivery (SGD) is usually determined using dilution of ... [more ▼]

Concomitant measurements of sytemic glucose delivery and carbohydrate oxidation are frequently performed in human investigations. Systemic glucose delivery (SGD) is usually determined using dilution of infused glucose tracers; net carbohydrate oxidation rate (net CHOOX) can be calculated from respiratory gas exchanges and urinary nitrogen excretion (indirect calorimetry); alternatively, glucose oxidation can be measured from labelled CO2 production during infusion of carbon-labelled glucose tracers. In this paper, the theory underlying the use of each of these techniques is briefly reviewed and qualitative differences are outlined. SGD represents the sum of hepatic glucogenolysis, gluconeogenesis from amino acids or glycerol, and, according to the glucose tracer used, glucose cycles (glucose-phosphate cycle, fructose-phosphate cycle, Cori and glucose-alanine cycles); systemic delivery of exogenous glucose after oral or i.v. glucose administration is also measured. Net CHOOX represents oxidation of glucose arising from hepatic or muscle glycogen or from exogenous glucose; it does not take into account oxidation of glucose formed from amino acids or glycerol, which is included in net protein or lipid oxidation. In contrast, isotopic determination of glucose oxidation corresponds to oxidation of glucose originating from hepatic glycogen breakdown, of exogenously administered glucose, and of glucose formed from amino acids and glycerol. Non-oxidative glucose disposal, calculated as SGD-net CHOOX, corresponds to the sum of gluconeogenesis from amino acids or glycerol (which are included in net protein and lipid oxidation), glucose cycles, and glycogen synthesis. [less ▲]

Detailed reference viewed: 13 (2 ULg)
See detailEffects of glucocorticoids and sympathomimetic agents on basal and insulin-stimulated glucose metabolism.
Paquot, Nicolas ULg; Schneiter, P.; Jequier, E. et al

in Clinical Physiology (1995), 15(3), 231-40

The mechanisms responsible for glucocorticoid-induced insulin resistance remain unclear. Glucocorticoids show several interactions with the sympatho-adrenal system which may contribute to this decrease in ... [more ▼]

The mechanisms responsible for glucocorticoid-induced insulin resistance remain unclear. Glucocorticoids show several interactions with the sympatho-adrenal system which may contribute to this decrease in insulin sensitivity: they enhance the synthesis and actions of catecholamines, but abolish insulin-induced activation of muscle sympathetic nerve activity. The present study was performed in order to investigate the effects of the interactions between glucocorticoids and the sympatho-adrenal system on insulin sensitivity. Basal and insulin-stimulated glucose metabolism was measured in healthy human subjects during four 2-h clamp studies as follows: control (C); after taking oral dexamethasone (2 mg daily) for 2 days (D); after taking oral ephedrine sulphate (40 mg daily) for 2 days (E); and after taking dexamethasone+ephedrine (D+E). Glucose uptake, production and oxidation were calculated from plasma 13C glucose and exhaled 13CO2 during constant tracer infusion of U-13C glucose. Basal glucose production, utilization and oxidation were similar in all four studies. During hyperinsulinaemia, glucose uptake was reduced by 51.5% with treatment D, by 25.9% with treatment E, and by 49.6% with D+E. Glucose oxidation was reduced by 54.0% with treatment D, by 24.0% with treatment E, and by 57.2% with D+E. Hepatic glucose production was completely suppressed in all four studies. It is concluded that both dexamethasone and ephedrine decrease insulin-mediated glucose uptake and oxidation. Co-administration of ephedrine does not suppress the glucocorticoid-induced alterations of glucose metabolism. This indicates that glucocorticoid-induced insulin resistance is not related to the inhibition of muscle sympathetic nerve activity. These results suggest instead that glucocorticoids and sympathomimetic agents may impair glucose metabolism by common actions. [less ▲]

Detailed reference viewed: 13 (1 ULg)
See detailLe rôle du foie dans l'homéostasie glucidique: une relecture des travaux de Claude Bernard
Lefebvre, P.; PAQUOT, Nicolas ULg; SCHEEN, André ULg

in Journées Annuelles de Diabetologie de l'Hôtel-Dieu (1995)

Detailed reference viewed: 26 (0 ULg)
See detailAspects hémodynamiques de l'insulinorésistance: des concepts théoriques à la thérapeutique.
Paquot, Nicolas ULg; SCHEEN, André ULg; Lefebvre, P.

in Médecine et Hygiène (1995), 53

Detailed reference viewed: 3 (0 ULg)
See detailEtiologie et physiopathologie du diabète de type 2.
SCHEEN, André ULg; PAQUOT, Nicolas ULg; Lefevre, P.

in Problèmes Actuels d'Endocrinologie et de Nutrition (1995), 10

Detailed reference viewed: 5 (0 ULg)
See detailComment explorer la sensibilite a l'insuline chez l'homme?
Scheen, André ULg; Paquot, Nicolas ULg; Letiexhe, Michel ULg et al

in Annales d'Endocrinologie (1995), 56(5), 523-30

The two most widely used methods for studying insulin sensitivity in man are the euglycaemic hyperinsulinaemic clamp and the intravenous glucose tolerance test with minimal model assessment. The glucose ... [more ▼]

The two most widely used methods for studying insulin sensitivity in man are the euglycaemic hyperinsulinaemic clamp and the intravenous glucose tolerance test with minimal model assessment. The glucose clamp is the reference method, well validated and easy to interpret, which allows various extensions to the basic experimental procedure in order to obtain more valuable information on the specific effects of insulin on the various aspects of glucose metabolism. However, it is time-consuming and labour-intensive. In contrast, the intravenous glucose tolerance test is easier to perform, but its interpretation is much more difficult and requires a modeling approach called the "minimal model". If the intravenous glucose tolerance test probably represents a good screening test, mainly on a population basis, the glucose clamp still remains the gold standard method to study insulin sensitivity in man. [less ▲]

Detailed reference viewed: 40 (0 ULg)
See detailAutorégulation de la production endogène de glucose
PAQUOT, Nicolas ULg; Schneiter, ph; Jequier, E. et al

in Cahiers de Nutrition et de Diététique (1995)

Detailed reference viewed: 4 (0 ULg)
See detailHepatic glucose metabolism after fructose ingestion in NIDDM and obses non diabetic subjects.
PAQUOT, Nicolas ULg; Tappy, L.; Schneiter, Ph et al

in Diabetes (1995), 44(suppl 1), 254

Detailed reference viewed: 3 (0 ULg)
See detailMétabolisme hépatique du glucose après ingestion de fructose chez des sujets obèses non diabétiques et diabétiques non insulinodépendants
PAQUOT, Nicolas ULg; Tappy, L.; Schneiter, ph et al

in Diabète & Métabolisme (1995), 21(suppl),

Detailed reference viewed: 15 (0 ULg)
See detailGlucose metabolism in obese subjects: lessons from OGTT, IVGTT and clamp studies.
Scheen, André ULg; Paquot, Nicolas ULg; Letiexhe, Michel ULg et al

in International Journal of Obesity & Related Metabolic Disorders (1995), 19 Suppl 3

Impaired glucose tolerance and overt diabetes are more frequent in presence than in absence of obesity. In obese subjects, glucose tolerance can be maintained within the normal range by compensating for ... [more ▼]

Impaired glucose tolerance and overt diabetes are more frequent in presence than in absence of obesity. In obese subjects, glucose tolerance can be maintained within the normal range by compensating for insulin resistance by peripheral hyperinsulinism, the latter resulting from both increased insulin secretion and reduced insulin clearance. Impaired glucose tolerance is observed when insulin resistance is associated to impaired first-phase insulin response, which results in a significant increase in plasma glucose levels and a late insulin hyperresponsiveness. Both hyperinsulinaemia and hyperglycaemia are then able to overcome peripheral insulin resistance and impaired glucose disposal. When a more marked defect in insulin secretion is present, hyperglycaemia progresses, probably due to an additional participation of impaired suppression of hepatic glucose output. Overt diabetes then occurs with persistent post-absorptive hyperglycaemia. All these abnormalities can be reversed after a marked weight loss and recovery of ideal body weight, arguing for acquired rather than inherited metabolic defects in presence of morbid obesity. If a sufficient weight reduction can not be obtained, pharmacological approaches may be considered to improve insulin resistance of obese subjects, especially those with impaired glucose tolerance or overt diabetes. [less ▲]

Detailed reference viewed: 25 (2 ULg)
See detailHow to Measure Insulin Action in Vivo
Scheen, A. J.; Paquot, Nicolas ULg; Castillo, M. J. et al

in Diabetes/Metabolism Reviews (1994), 10(2), 151-88

Detailed reference viewed: 11 (0 ULg)